Webcast ImageWebcast
BioTime, Inc. at Oppenheimer 27th Annual Healthcare Conference  (Replay)
03/21/17 at 3:55 p.m. ET
BioTime, Inc. at Oppenheimer 27th Annual Healthcare Conference
Tuesday, March 21, 2017 3:55 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
December 14, 2016BioTime Achieves Patient Recruitment Milestone in Renevia Pivotal Trial
Crosses Milestone of 50 Patients Randomized in Pivotal Trial Remains on Track for Top-Line Data by Middle of 2017 ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 14, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced that it has achieved an important patient enrollment milestone in its Renevia® pivotal trial in Europe. The company now ha... 
Printer Friendly Version
December 12, 2016BioTime to Present at Global Bioproduction Summit
Co-CEO Dr. Michael West to Discuss Human Cell Manufacturing for Regenerative Medicine ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 12, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a presentation at the Global Bioproduction Summit, December 12-13, at the Hilton ... 
Printer Friendly Version
December 08, 2016BioTime Co-CEO Dr. Michael D. West to Deliver Plenary Presentation on the Field of Induced Tissue Regeneration at World Stem Cell Summit
Presentation Will Describe the Future of Aging Research and iTRTM, an Emerging Area of Research from BioTime Dr. West to also Serve on Panel: “Unleashing Regenerative Medicine to Extend the Healthy Lifespan” ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 8, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executiv... 
Printer Friendly Version
November 18, 2016Positive Early Data From BioTime’s Renevia Pivotal Trial Presented at IFATS Meeting
-3D-imaging Suggests Grafts Retained Volume Over the Assessment Period- -Cells Remained Viable and Proliferated in Renevia Hydrogel- ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 18, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company with a focus on pluripotent cell-based technologies, announced details of positive data from its Renevia® pivotal trial, reported via a presentation at the 14th annual International Fede... 
Printer Friendly Version
November 10, 2016BioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016
-Will Also Present at Young Jewish Professionals Life Sciences & Pharmaceuticals CEO Symposium- ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is participating at two conferences during the week of November 14. On Monday, November 14, Dr. ... 
Printer Friendly Version
November 03, 2016BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress
Initial data from OpRegen® trial suggest cells able to engraft and survive at least 12 months Initial 3-D Imaging data from Renevia® trial run-in patients suggest volumetric improvements are sustained at least 12 months ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 3, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology company with a focus on pluripotent cell-based technologies, today re... 
Printer Friendly Version
November 01, 2016Data From BioTime’s Renevia Pivotal Trial in HIV-Associated Facial Liopatrophy to be Presented at the 14th Annual IFATS Meeting on November 17
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 1, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that an abstract evaluating Renevia® in ‘run-in’ patients with HIV-associated facial lipoatrophy from the Renevia-02 trial will be presented at the 14th annual International Federation for Adipose Therapeutics and Science meeting (IFATS) taking place from November ... 
Printer Friendly Version
October 31, 2016BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development
Brings Wealth of Value Creation Experience to BioTime ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 31, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that the company has appointed Jim Knight as Senior Vice President, Head of Corporate Development. He reports to Adi Mohanty, Co-Chief Executive Officer. In his new role, Mr. Knight will oversee bus... 
Printer Friendly Version
October 24, 2016BioTime, Inc. to Announce Third Quarter Results on November 3, 2016
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 24, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that it will release third quarter financial and operating results on Thursday, November 3, 2016, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, November 3, 2016, at 4:30 p.m. Eastern Time / 1:30 p.m. ... 
Printer Friendly Version
October 20, 2016First Patient Cohort Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to Be Presented at ISOPT Clinical Symposium on December 2, 2016
- OpRegen at the first dose caused no serious adverse events in the first patient cohort - - Retinal imaging suggests presence and survival of the transplanted cells in the subretinal space for up to one year - ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 20, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today reported that data from the first patient... 
Printer Friendly Version
October 13, 2016BioTime to Present at the BIO Investor Forum
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 13, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty, Co-Chief Executive Officer, will be presenting at the BIO Investor Forum on Wednesday, October 19, 2016, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The BIO Investor Forum is being held at the Westin St. Francis Hotel in San Francisco. ... 
Printer Friendly Version
September 23, 2016BioTime to Webcast Presentation at the Ladenburg Thalmann 2016 Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 23, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the Ladenburg Thalmann 2016 Healthcare Conference in New York City on Tuesday, September 27, 2016, at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time. The Ladenburg Thalmann Healthcare Conference is a well-respected event ... 
Printer Friendly Version
September 06, 2016BioTime to Present at Two Upcoming Investor Conferences
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 6, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the following investor conferences: 2016 Gateway Conference at the Four Seasons Hotel, San Francisco, Wednesday, September 7, 2016, at 11:00am ET (8:00am PT) 18th Annual Rodman & Renshaw Globa... 
Printer Friendly Version
August 15, 2016BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine
New Patents Supplement Existing Portfolio of More Than 700 Patents and Patent Applications Owned or Licensed by BioTime Family of Companies Worldwide ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 15, 2016-- BioTime, Inc. (NYSE MKT:BTX) today announced the issuance of 31 new patents between July 3, 2015 and August 3, 2016 that are owned by or licensed to BioTime, or its family of companies. The new patents add to the over 700 issued and pending patent... 
Printer Friendly Version
August 09, 2016BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments
Therapeutic Candidates Continue Clinical Progress Deconsolidation Simplifies Financials Successful Public Equity Offering Strengthens Balance Sheet ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 9, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the second quarter ended June 30, 2016 and ... 
Printer Friendly Version
July 27, 2016BioTime, Inc. to Report Second Quarter Results on August 9, 2016
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 27, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will release second quarter financial and operating results on Tuesday, August 9, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Tuesday, August 9, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to... 
Printer Friendly Version
July 13, 2016Landmark Stem Cell Clinical Trial Procedure Performed at Santa Clara Valley Medical Center
– July 13, 2016 /Press Release/ –Santa Clara County, CA. Last week, physicians at Santa Clara Valley Medical Center (SCVMC), in partnership with Stanford Medicine, successfully completed a surgery injecting stem cells into the spinal cord of a patient who had recently suffered a severe spinal cord injury. The patient became one of a handful of people in the world who have undergone this procedure as part of this clinical trial.Stem cells have the potential to regenerate new tissues and... 
Printer Friendly Version
July 05, 2016BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 5, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced that the underwriters of BioTime, Inc.’s previously announced public offering that initially closed on June 21, 2016, have purchased an additional 1,098,326 shares of BioTime, Inc.’s common stock at a price of $2.39 per share,... 
Printer Friendly Version
June 29, 2016BioTime Presents Online Resource for Applying Artificial Intelligence to Stem Cell Biology at Mensa 2016 Annual Gathering
- Deep Learning Algorithms have the potential to unlock mechanisms of tissue regeneration for applications in age-related disease - ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 29, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that Co-CEO Dr. Michael D. West, will give a lecture at the Mensa Annual Gathering today titled, "Hayflick Rewound: Implications of Reversing the Aging of Human Cells." Dr.... 
Printer Friendly Version
June 21, 2016BioTime, Inc. Announces Closing of Public Offering of Common Stock
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 21, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the closing of its previously announced underwritten public offering. BioTime, Inc. sold 7,322,176 shares of its common stock in the offering. The offering price was $2.39 per share and gross proceeds to BioTime, Inc. are appr... 
Printer Friendly Version
June 16, 2016BioTime, Inc. Announces Pricing of Public Offering of Common Stock
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 16, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the pricing of an underwritten public offering of 7,322,176 shares of its common stock at a public offering price of $2.39 per share. The gross proceeds to BioTime, Inc. from this offering are expected to be approximately $17... 
Printer Friendly Version
June 15, 2016BioTime, Inc. Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 15, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may... 
Printer Friendly Version
June 13, 2016BioTime’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort in Clinical Trial for Dry-AMD
- Safety Confirmed with No Concerns Reported in Cohort 1 - - Approval to Immediately Proceed to Cohort 2 - ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Jun. 13, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) and Cell Cure Neurosciences Ltd. (Cell Cure), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Data Safety Monitoring Board (DSMB), an independent group of medic... 
Printer Friendly Version
June 10, 2016BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program
- Israel Innovation Authority awards a grant to Cell Cure Neurosciences, a BioTime Subsidiary, that will support ongoing development of OpRegen®, to address a leading cause of blindness, dry-AMD - This is the 10th year in receipt of an Israeli Government grant in support of Cell Cure ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Jun. 10, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine co... 
Printer Friendly Version
June 09, 2016BioTime to Present at the Jefferies 2016 Global Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 9, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the company will present at the Jefferies 2016 Global Healthcare Conference to be held in New York on June 7-10, 2016. Russell Skibsted, BioTime’s Chief Financial Officer, will provide an overview and an update on product development at 1:30 PM EDT on Friday, ... 
Printer Friendly Version
May 20, 2016BioTime to Present at Two Upcoming Investor Conferences
ALAMEDA, Calif.--(BUSINESS WIRE)--May 20, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) announced that Co-Chief Executive Officer Michael D. West, Ph.D., will present at the 2016 Oppenheimer 17th Annual Israel Conference to be held at the David Intercontinental Hotel in Tel-Aviv on Sunday, May 22, 2016. Dr. West will also present at the Mauldin Economics 2016 Strategic Investment Conference, in Dallas, Texas on May 25, 2016. The conference ... 
Printer Friendly Version
May 10, 2016BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
- First Cohort in OpRegen® Trial Completed - Management to Host Investor Conference Call on May 17, 2016 at 4:30 p.m. ET ALAMEDA, Calif.--(BUSINESS WIRE)--May 10, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the first quarter ended March 31, 2016 and provided a corporate update. The Company also announ... 
Printer Friendly Version
April 26, 2016BioTime Co-CEO Dr. Michael West Presents at Biomedical Innovation for Healthy Longevity, International Conference
Presentation topics include: • BioTime’s Products in Development Addressing the Large and Growing Markets in Age-Related Degenerative Disease; and • New Insights into the Fundamental Biology of Human Aging ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 26, 2016-- BioTime, Inc. (NYSE MKT:BTX) announced that Co-Chief Executive Officer Michael D. West, Ph.D. delivered a presentation today at “Biomedical Innovation for Healthy Long... 
Printer Friendly Version
March 21, 2016BioTime, Inc. to Host Conference Call to Update Investors on Recent Accomplishments and Corporate Objectives for 2016
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 21, 2016-- BioTime, Inc. (NYSE MKT:BTX) today announced that it will host a conference call on Thursday, March 31, to update investors on the Company’s recent accomplishments and objectives for the remainder of 2016. Among the highlights of the call will be an update on the clinical trials currently underway for Renevia® for lipoatrophy, and OpRegen® for dry age-related macular degeneration. In addition, management ... 
Printer Friendly Version
February 24, 2016BioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for Immunotherapy in Acute Myeloid Leukemia
-- Provides Direction for Late-Stage Development of AST-VAC1 in Acute Myeloid Leukemia -- ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 24, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its subsidiary, Asterias Biotherapeutics (“Asterias”), has successfully completed an End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) f... 
Printer Friendly Version
February 16, 2016BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents
FREMONT, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 16, 2016-- Asterias Biotherapeutics, Inc. (NYSE MKT:AST) and BioTime, Inc. (NYSE MKT and TASE:BTX), both clinical-stage regenerative medicine companies with a focus on pluripotent stem cell technology, and BioTime’s wholly owned subsidiary ES Cell International Pte Ltd (“ESI”), have entered into a Share Transfer Agreement through which BioTime will re-acquire from Asterias shares of capital sto... 
Printer Friendly Version
February 01, 2016BioTime, Inc. to Present at Three Investor Conferences in February
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 1, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, announced today that it will present at the following three investor conferences in February: 18th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 9 at 2:00 p.m. ET Source Capital Group’s 2016 Disruptive G... 
Printer Friendly Version
January 12, 2016Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 12, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) announced today that pursuant to Section 6.1(c) of the Warrant Agreement dated as of October 1, 2013, as amended September 19, 2014, between BioTime and American Stock Transfer & Trust Company LLC as Warrant Agent (the “Warrant Agreement”) governing the BioTime Common Share Purchase Warrants Expiring October 1, 2018 (the “Warrants”), the Board of Directors of Bio... 
Printer Friendly Version